# Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

> **NCT02612298** · PHASE4 · COMPLETED · sponsor: **Sumitomo Pharma (Suzhou) Co., Ltd.** · enrollment: 198 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Arotinolol Hydrochloride
- **DRUG:** Metoprolol succinate sustained-release tablet

## Key facts

- **NCT ID:** NCT02612298
- **Lead sponsor:** Sumitomo Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-09-13
- **Final completion:** 2018-09-13
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2019-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612298, "Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02612298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*